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In this issue of Cancer Cell, Kovacic and colleagues have reexamined the role of STAT1 in murine models of leukemogenesis. 
Their studies shed new light on the complex interplay between cell-autonomous contributions and host responsiveness to 
cancer and elucidate a previously unknown role of STAT1 in tumor progression.Available evidence has indicated that 
STAT1 has tumor suppressor activity, in 
that more rapid tumor progression has 
been observed in STAT1-deficient mice 
(e.g., Lesinski et al., 2003; Shankaran et 
al., 2001). In consonance with previous 
reports, Kovacic et al. (2006) show that 
v-abl-mediated transformation of hema-
topoietic cells derived from STAT1−/− ani-
mals contributes to increased number of 
growth factor-independent pro-B colonies 
in vitro.
However, when low numbers of 
cells from v-abl-transformed pro-B cell 
lines were injected into immunodeficient 
RAG2−/− recipient mice, STAT1 deficiency 
impaired rather than enhanced leuke-
mia progression in vivo. These findings 
suggested cell-nonautonomous contri-
butions to disease development, with 
innate immune surveillance as a potential 
mechanism. Kovacic and colleagues dem-
onstrated, consistent with the published 
literature (Lee et al., 1999), that STAT1−/− 
tumors expressed low levels of MHC class 
I. Although RAG2−/− mice lack functional 
T cells, B cells, or NKT or γδT cells, they 
have fully functional NK cells that mediate 
tumor surveillance in part through recog-
nizing as nonself, and destroying, cells 
that express low levels of MHC class I. 
Evidence that supports an important role 
for MHC class I in these experiments 
includes the observation that restora-
tion of MHC class I restored the leuke-
mogenic potential of v-abl-transformed 
STAT1−/− cells. Furthermore, in those 
animals in which disease did develop, the 
v-abl-transformed STAT1−/− leukemic cells 
showed evidence of in vivo “immunoedit-
ing” (Shankaran et al., 2001) with appar-
ent selection for leukemia cells that had 
acquired stable high-level expression of 
MHC class I.
Of interest, these investigators also 
assessed the potential role of STAT1 in NK 
cell function, based on previous reports 
that STAT1−/− NK cells had reduced cyto-
toxic activity (Lee et al., 2000a). They 
demonstrated that STAT1−/− NK cells, 
despite reduced cytotoxic activity, could cancer cell 10, July 2006 ©2006 ElsEviEr inckill v-abl-transformed STAT1−/−, but not v-
abl-transformed STAT1+/−, leukemia cells. 
In consonance with these in vitro findings, 
there was an attenuated, but not abrogat-
ed, leukemia phenotype in STAT1−/− neo-
nates transduced with v-abl retrovirus, with 
6/28 animals remaining healthy for more 
than 8 months, whereas all STAT1+/− ani-
mals succumbed to disease. Furthermore, 
among the 22 STAT1−/− animals that did 
develop disease, there was increased 
MHC class I expression on leukemic cells, 
consistent with an immunoediting activity 
in vivo. It is important as well to note that 
the observed defects in STAT1−/− mice are 
quite different than those observed with 
IFN-γ−/− mice, suggesting that aberrancies 
in the STAT1−/− context may be due in part 
to IFN-independent mechanisms (Lee et 
al., 2000b).
Another interesting point that can 
be gleaned from the cumulative data 
is the very delicate balance between 
cell-autonomous and -nonautonomous 
contributions to phenotype—referred 
to by the authors as an “evolutionary 
arms race” in tumorigenesis. These data 
derived from transplantation into RAG2−/− 
mice provide additional support for the 
importance of innate immunity mediated 
by NK cells, in addition to involvement 
of acquired tumor immunity mediated by 
T and B cells. It would be of interest to 
test these findings in mice deficient in 
NK cells (such as FLT3−/−-deficient ani-
mals) to obtain insights into the relative 
contributions of innate versus acquired 
immunity in this model.
The delicate balance in tumorigenic 
potential versus cell-nonautonomous 
tumor surveillance is exemplified in sever-
al experiments. For example, v-abl-trans-
formed STAT1−/− cells show an attenuated 
phenotype, presumably due to decreased 
expression of MHC class I. But this finding 
is dependent on use of low cell doses, and 
in instances where leukemia develops the 
STAT1−/− leukemia cells have been “immu-
noedited” by NK cells to include only those 
that now express high levels of MHC class 
I. Furthermore, although STAT1−/− NK cells . are defective in cytotoxic activity, they 
can still attenuate leukemic phenotypes 
engendered by STAT1−/− leukemic cells. 
In contrast, fully competent STAT+/− NK 
cells could efficiently eradicate STAT1−/− 
leukemic cells, but not STAT1+/− cells that 
express high levels of MHC class 1. These 
observations provide some insight into the 
complexities and challenges—and thus 
far limited success—of manipulating host 
immunity to improve outcome in treat-
ment of human cancers. Tumor burden 
is clearly an important issue, as are host 
determinants of both innate and humoral 
immunity. Murine models, such as the one 
described here, should enable detailed 
study of this complex interplay.
It is not yet clear whether the find-
ings in this model system can be broadly 
extrapolated, or the extent to which these 
mouse models of immune surveillance 
might inform therapeutic strategies in 
humans. The authors suggest that loss of 
STAT1 may be relevant in other contexts, 
including leukemia initiated by v-abl-trans-
formed STAT1−/− cells in immunocom-
petent hosts such as Balb/C. However, 
the v-abl allele is not a known cause of 
hematological malignancies in humans. 
Another activated ABL allele, BCR-ABL, 
is associated with chronic myelogenous 
leukemia (CML) in humans. But, CML 
is a special case among hematopoietic 
malignancies in being highly responsive 
to IFN therapy. Thus, it will be important 
to test other leukemogenic alleles in addi-
tion to activated ABL. Limited analysis of 
the rare TEL-JAK2 allele is provided but 
focuses on erythroid progenitors that are 
not a feature of the spectrum of TEL-
JAK2 leukemias in humans, and curi-
ously shows significant attenuation of 
phenotype in a RAG2−/− γC−/− background 
compared to Balb/C, though no differ-
ence was observed in that background 
between STAT+/− and STAT1−/− leukemic 
cells. Additional analysis will be neces-
sary to determine to what extent these 
phenomena can be extrapolated to sev-
eral of the more common human hema-
tological malignancies.
	 p r e v i e w sHowever, there are several key points 
that emanate from this interesting report. 
These findings serve as an important 
extension of the concept of immunoed-
iting in tumor surveillance (Shankaran 
et al., 2001), and the importance of NK 
cells in shaping the phenotypic charac-
teristics of tumors. These data corrobo-
rate and support previous findings on the 
role of STAT1 in NK cell function, and in 
regulation of MHC class I expression. It 
seems likely, based on these data, that 
there will be functions of STAT1 that are 
both dependent and independent of type 
I IFN signaling, an arena that should be 
of considerable interest for further investi-
gation. These experiments also elegantly 
demonstrate the value of modeling cancer 
in vivo in murine models of disease, and 
the importance of in vivo experimentation 
to dissect out the evolutionary “winner” in 2 
High-throughput techniques are identify-
ing remarkable heterogeneity in the can-
cer genome, implying that dysregulation 
of numerous genes and pathways can 
lead to oncogenesis and cancer progres-
sion. Furthermore, as cancers progress, 
they demonstrate genomic instability, 
leading not only to the acquisition of muta-
tions conferring selective advantages, but 
also to noncontributing bystander lesions. 
With plans to characterize all mutations 
in human cancers, such as The Cancer 
Genome Atlas (Bonetta, 2005), novel 
techniques to identify the lesions driving 
oncogenesis/metastasis from secondary 
mutations are urgently needed. Two stud-
ies by Zender et al. (2006) and Kim et al. 
(2006) in the June 30 issue of Cell dem-
onstrate the usefulness of comparative 
oncogenomic approaches using defined 
mouse models to identify driving genes 
Of mice and men: Can
using comparative on
With the proliferation of high-throughpu
bystander genetic events are needed. Tw
models to serve as biological filters to m
of mouse tumor models and human tumo
NEDD9 was identified as a metastasis g
oncogenomics approach can identify gencell-autonomous tumor-promoting activ-
ity, in apposition to cell-nonautonomous 
host immune response—in this case each 
attributable to deficiency of the same 
allele, STAT1. Finally, this report dem-
onstrates an expanding paradigm that 
some gene products may serve both as 
tumor suppressors and as tumor promot-
ers. Ultimately, clear insights into these 
pathogenetic processes should inform 
more effective therapeutic approaches to 
cancer.
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Comparative oncogenomics identi-
fies cIAP1 and Yap as driving onco-
genes in hepatocellular carcinoma
In the study by Zender et al., the authors 
isolated hepatoblasts from the liver of 
p53−/− mice and overexpressed Myc, acti-
vated Akt, or oncogenic Ras before rein-
troducing these cells into recipient mice 
livers. They focused on tumors develop-
ing from p53−/−;myc-induced hepatoblasts, 
which were histologically consistent with 
human hepatocellular carcinomas (HCCs). 
In an effort to identify spontaneously 
acquired lesions contributing to tumori-
genesis, they used a form of array com-
parative genomic hybridization (aCGH) 
termed representational oligonucleotide 
microarray analysis (ROMA) to search 
for focal regions of copy number change. 
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By ROMA, four of seven Myc-driven HCCs 
contained a focal amplicon (containing 12 
genes) on chromosome 9qA1.
Using the mouse model as a biological 
filter, the authors interrogated 48 human 
HCCs profiled in parallel. Intriguingly, two 
of these human HCCs harbored focal 
amplifications on chromosome 11q22 
(syntenic to mouse 9qA1). To identify the 
driving gene, the authors determined the 
expression of all overlapping genes from 
the syntenic amplicons. Not one, but two 
genes, cIAP1 and Yap, showed increased 
expression at the mRNA and protein level 
in all mouse and human tumors contain-
ing the amplicon.
To confirm the oncogenic effects of 
cIAP1 and Yap in vivo, the authors overex-
pressed these two genes in the p53−/−;myc 
hepatoblasts that were used to generate 
the tumors. Expression of cIAP1 or Yap 
e, methods to distinguish causal from 
al. in Cell use genetically defined mouse 
of high-resolution copy number profiles 
 human hepatocellular carcinoma, while 
eports demonstrate that a comparative 
etastasis.
